Introduction {#s1}
============

Roux-en-Y gastric bypass (RYGB) results in sustained weight loss ([@B1],[@B2]) and has been proposed as a treatment for type 2 diabetes mellitus (T2DM) ([@B3],[@B4]). The Diabetes Surgery Study (DSS) randomized patients to lifestyle modification and intensive medical management (LS/IMM) with or without RYGB ([@B5]). At 1 year, RYGB patients achieved greater weight loss and superior improvement in HbA~1c~ ([@B5]).

In addition to caloric restriction and weight loss, RYGB also changes gastrointestinal transit time and nutrient flow, leading to altered nutrient absorption and gut hormone secretion that may further improve insulin sensitivity and β-cell function ([@B2]). To elucidate the mechanisms contributing to improved glycemia after RYGB, we performed an ancillary investigation to the DSS to assess changes in gut hormones and glucagon levels, insulin sensitivity, and insulin secretion in response to enteral stimulus. We hypothesized that greater β-cell function at baseline would be predictive of an improvement in glucose tolerance and correlate with specific gut hormone changes.

Research Design and Methods {#s2}
===========================

Study Participants {#s3}
------------------

Details of the study methods have been published ([@B5],[@B6]). Key inclusion criteria included BMI 30--39.9 kg/mg^2^; HbA~1c~ ≥8% (64 mmol/mol) or ≤14% (130 mmol/mol); and C-peptide \>1 ng/mL 90 min after a standardized meal challenge. The 68 patients in this ancillary study were from two of the five study sites that recruited a total of 120 participants.

Interventions {#s4}
-------------

Details of the RYGB and LS/IMM intervention, including the protocol for intensification of medical therapy, have been described ([@B5]). Blood specimens were collected before and 15, 30, 60, 90, and 120 min after ingestion of Ensure over 15 min in the morning while upright. Insulin was held the prior evening, and other diabetes medications were held the morning of testing.

Assays {#s5}
------

Assays used for determination of hormone concentrations were as follows: *1*) insulin and C-peptide were measured using the Immulite Analyzer; *2*) total glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), and gastric inhibitory polypeptide (GIP) were measured by ELISA (Millipore); and *3*) glucagon was measured by radioimmunoassay (Millipore).

Calculations and Statistical Analysis {#s6}
-------------------------------------

The insulinogenic index and C-peptide index were quantified as the change in insulin or C-peptide relative to the change in glucose from 0 to 30 min. The insulin secretion rate (ISR) was calculated by deconvolution of C-peptide through the Chronological Series Analyzer software ([@B7],[@B8]). HOMA-insulin resistance (IR) was calculated as reported by Matthews et al. ([@B9]). The Matsuda index (MI) was calculated as 10,000/(glucose~0~ × insulin~0~ × mean glucose × mean insulin)^0.5^ ([@B10],[@B11]). The oral disposition index (oDI) was calculated as the product of the MI and the ratio of insulin secretion relative to glucose. Insulin clearance was calculated as the ratio of fasting C-peptide to fasting insulin. The metabolic clearance rate (MCR) of insulin was calculated as the ratio of the total insulin secretion area under the curve (AUC) to the plasma insulin AUC. β-Cell glucose sensitivity (BCGS) was calculated as the slope between ISR and the corresponding blood glucose, from baseline to glucose at 30 min after meal consumption. AUC was calculated using the trapezoidal rule.

Data are presented as mean values ± SEM. Differences at baseline for continuous variables were assessed with *t* tests and for categorical variables with χ^2^ or the Fisher exact test. Change from baseline was calculated for each patient using paired *t* tests. Between-group differences in change between baseline and 12 months were assessed using two-sample *t* tests. SAS 9.3 software (SAS Institute Inc., Cary, NC) was used for statistical analysis. A two-sided *P* value \<0.05 was considered statistically significant. There was no adjustment for multiple comparisons.

Results {#s7}
=======

Clinical Characteristics of Study Participants {#s8}
----------------------------------------------

Sixty-eight patients were randomized to LS/IMM (41% women) or RYGB (62% women). Mean age (50 ± 1 years), duration of T2DM (10.5 ± 0.7 years), BMI, and HbA~1c~ were similar between the groups ([Table 1](#T1){ref-type="table"}). Weight loss was greater after RYGB, and diabetes medications were reduced.

###### 

Clinical characteristics and changes in glucostatic parameters and gut hormones

                                                            IMM                                        *P*[\*](#t1n1){ref-type="table-fn"}            RYGB       *P*[\*](#t1n1){ref-type="table-fn"}        *P*[†](#t1n2){ref-type="table-fn"}                       
  --------------------------------------------------------- ------------------------------------------ ---------------------------------------------- ---------- ------------------------------------------ --------------------------------------------- ---------- ----------
  BMI (kg/m^2^)                                             35.7 ± 0.6                                 32.3 ± 0.7[§](#t1n4){ref-type="table-fn"}      \<0.0001   35.8 ± 0.5                                 25.7 ± 0.5[§](#t1n4){ref-type="table-fn"}     \<0.0001   \<0.0001
  Weight (kg)                                               105.7 ± 2.9                                96.1 ± 3.0[§](#t1n4){ref-type="table-fn"}      \<0.0001   103.2 ± 2.3                                74.2 ± 2.2[§](#t1n4){ref-type="table-fn"}     \<0.0001   \<0.0001
  Weight loss (%)                                           ---                                        9.2 ± 1.3                                      ---        ---                                        28.1 ± 1.3                                    ---        \<0.0001
  T2DM medications, *n* (%)                                                                                                                                                                                                                                          
   Orals (except DPP-IV)                                    33 (97.1)[‡](#t1n3){ref-type="table-fn"}   30 (88.2)[§](#t1n4){ref-type="table-fn"}       0.21       27 (79.4)[‡](#t1n3){ref-type="table-fn"}   14 (41.2)[§](#t1n4){ref-type="table-fn"}      0.002      0.83
   Incretin therapy                                         10 (29.4)                                  31 (91.2)[§](#t1n4){ref-type="table-fn"}       \<0.0001   5 (14.7)                                   7 (20.6)[§](#t1n4){ref-type="table-fn"}       0.57       0.002
   Insulin                                                  15 (44.1)[‡](#t1n3){ref-type="table-fn"}   15 (44.1)                                      1          25 (73.5)[‡](#t1n3){ref-type="table-fn"}   9 (26.5)                                      \<0.0001   0.0007
   All T2DM medications                                     34 (100)                                   34 (100)[§](#t1n4){ref-type="table-fn"}        1          34 (100)                                   27 (79.4)[§](#t1n4){ref-type="table-fn"}      0.01       0.01
  HbA~1c~ (%)                                               9.6 ± 0.2                                  7.4 ± 0.3[§](#t1n4){ref-type="table-fn"}       \<0.0001   9.8 ± 0.2                                  6.4 ± 0.2[§](#t1n4){ref-type="table-fn"}      \<0.0001   0.0004
  HbA~1c~ (mmol/mol)                                        81 ± 2.2                                   57 ± 3.3[§](#t1n4){ref-type="table-fn"}                   84 ± 2.2                                   46 ± 2.2[§](#t1n4){ref-type="table-fn"}                  
  Glucose~F~ (mg/dL)                                        220 ± 8                                    151 ± 8[§](#t1n4){ref-type="table-fn"}         \<0.0001   236 ± 14                                   117 ± 6[§](#t1n4){ref-type="table-fn"}        \<0.0001   0.005
  Glucose~120m~ (mg/dL)                                     252 ± 12                                   159 ± 10[§](#t1n4){ref-type="table-fn"}        \<0.0001   268 ± 10                                   128 ± 9[§](#t1n4){ref-type="table-fn"}        \<0.0001   0.01
  Insulin~F~ (µIU/mL)                                       24.3 ± 3.3                                 20.1 ± 3.1[§](#t1n4){ref-type="table-fn"}      0.34       27.3 ± 4.7                                 7.2 ± 1.6[§](#t1n4){ref-type="table-fn"}      \<0.0001   0.008
  C-peptide~F~ (ng/mL)                                      3.4 ± 0.3                                  3.4 ± 0.3[§](#t1n4){ref-type="table-fn"}       0.82       2.8 ± 0.3                                  1.7 ± 0.2[§](#t1n4){ref-type="table-fn"}      0.0003     0.01
  C-peptide~90m~ (ng/mL)                                    5.4 ± 0.5                                  6.3 ± 0.5                                      0.005      4.0 ± 0.4                                  3.8 ± 0.3                                     0.60       0.02
  30-min insulinogenic index (μIU × dL × mL^−1^ × mg^−1^)   0.30 ± 0.05                                0.35 ± 0.06[§](#t1n4){ref-type="table-fn"}     0.40       0.24 ± 0.04                                0.51 ± 0.09[§](#t1n4){ref-type="table-fn"}    0.006      0.04
  30-min C-peptide index (ng × dL × mL^−1^ × mg^−1^)        0.041 ± 0.01                               0.036 ± 0.006[§](#t1n4){ref-type="table-fn"}   0.69       0.024 ± 0.003                              0.065 ± 0.01[§](#t1n4){ref-type="table-fn"}   0.0003     0.0025
  Insulin clearance, C~F~/I~F~ (ng/µIU)                     0.20 ± 0.02                                0.31 ± 0.04                                    0.01       0.17 ± 0.02                                0.40 ± 0.04                                   \<0.0001   0.046
  MCR (kg × mL × min^−1^)                                   353 ± 29                                   1,163 ± 96                                     \<0.0001   281 ± 28                                   1,162 ± 79                                    \<0.0001   0.51
  HOMA-IR (mmol × µIU × L^−2^)                              12.5 ± 1.9                                 7.6 ± 1.3[§](#t1n4){ref-type="table-fn"}       0.04       14.7 ± 2.1                                 2.2 ± 0.5[§](#t1n4){ref-type="table-fn"}      \<0.0001   0.01
  MI \[1/(mmol/L)^2^ × (pmol/L)^2^\]                        2.2 ± 0.2                                  5.0 ± 0.9[§](#t1n4){ref-type="table-fn"}       0.001      2.7 ± 0.5                                  9.1 ± 1.0[§](#t1n4){ref-type="table-fn"}      \<0.0001   0.004
  oDI (I~AUC~/glucose~AUC~ × MI)                            0.23 ± 0.02                                0.61 ± 0.08[§](#t1n4){ref-type="table-fn"}     \<0.0001   0.20 ± 0.02                                1.35 ± 0.16[§](#t1n4){ref-type="table-fn"}    \<0.0001   \<0.0001
  BCGS (pmol × kg^−1^ ×min^−1^)/(mg/dL)                     18.6 ± 4.2                                 19.7 ± 4.0                                     0.74       11.5 ± 2.4                                 31.2 ± 5.0                                    0.002      0.007
  Adiponectin (mg/mL) × 10^3^                               3.2 ± 0.5                                  3.6 ± 0.6[§](#t1n4){ref-type="table-fn"}       0.13       2.8 ± 0.5                                  6.6 ± 0.9[§](#t1n4){ref-type="table-fn"}      \<0.0001   \<0.0001
  GLP-1 (pmol/L)                                            23.6 ± 2.3                                 24.0 ± 2.4[§](#t1n4){ref-type="table-fn"}      0.81       19.1 ± 2.2                                 13.9 ± 1.6[§](#t1n4){ref-type="table-fn"}     0.02       0.05
  GIP (pg/mL)                                               94.8 ± 7.6                                 103.3 ± 14.4                                   0.57       115.6 ± 17.0                               83.1 ± 6.9                                    0.06       0.07
  GLP-2 (ng/mL)                                             7.0 ± 0.6                                  5.7 ± 0.5[§](#t1n4){ref-type="table-fn"}       0.03       5.7 ± 0.5                                  4.1 ± 0.6[§](#t1n4){ref-type="table-fn"}      0.005      0.63
  Glucagon (pg/mL)                                          93.0 ± 7.5                                 80.8 ± 5.1[§](#t1n4){ref-type="table-fn"}      0.02       83.8 ± 4.9                                 66.7 ± 3.3[§](#t1n4){ref-type="table-fn"}     0.0005     0.47
  Insulin~F~/glucagon~F~                                    7.3 ± 1.1                                  6.2 ± 0.9[§](#t1n4){ref-type="table-fn"}       0.39       8.2 ± 1.6                                  2.8 ± 0.6[§](#t1n4){ref-type="table-fn"}      0.0001     0.02
  Insulin~120m~/glucagon~120m~                              9.9 ± 1.2                                  11.8 ± 1.6[§](#t1n4){ref-type="table-fn"}      0.22       12.3 ± 2.9                                 4.7 ± 0.9[§](#t1n4){ref-type="table-fn"}      0.003      0.001
  Insulin~AUC~/glucagon~AUC~                                20.4 ± 2.8                                 23.7 ± 3.2                                     0.27       22.5 ± 4.8                                 17.4 ± 2.6                                    0.11       0.05

Values are mean ± SEM or *n* (%).

AUC is calculated from 0 to 120 min.

Molar ratios for insulin/glucagon are presented.

C, C-peptide; DPP-IV, dipeptidyl peptidase-4; F, fasting; I, insulin.

\**P* = within group change.

†*P* = difference in the change over time between groups.

‡*P* \< 0.05 between groups at baseline.

§*P* \< 0.05 between groups at 12 months.

Glucostatic Parameters {#s9}
----------------------

After 1 year, RYGB patients had significantly lower fasting glucose and HbA~1c~ ([Table 1](#T1){ref-type="table"}). Glucose AUC decreased comparably after both interventions, but postprandial glucose after RYGB peaked earlier and decreased more precipitously ([Fig. 1](#F1){ref-type="fig"}). Fasting insulin and C-peptide decreased only after RYGB. Despite greater early postprandial insulin levels, the insulin AUC was lower after RYGB; the C-peptide AUC increased in both groups ([Fig. 1](#F1){ref-type="fig"}). The insulinogenic index and C-peptide index both increased more than twofold only after RYGB.

![Glucostatic and pancreatic hormone changes. Changes in glucose (*A*), insulin (*B*), C-peptide (*C*), and glucagon (*D*). *E*: Changes in insulin secretion relative to glucose. *F*: Changes in metabolic insulin clearance. *G*: MI at baseline. *H*: MI after 1 year. *I*: Regression analysis of MI after 1 year and percentage of weight loss. *J*: Regression analysis of oDI after 1 year and percentage of weight loss. LS/IMM is depicted in blue and RYGB is depicted in red. Open shapes and dashed lines denote baseline values, and closed shapes and solid lines denote values at 1 year. Hatched bars denote baseline values, and solid bars denote values at 1 year. AUC is calculated from 0 to 120 min and is expressed ×10^3^. M0, month 0 (baseline); M12, month 12. \**P* \< 0.05 for within-group change. §*P* \< 0.05 for difference in change between groups.](db141870f1){#F1}

Fasting glucagon decreased in both groups. The glucagon AUC also decreased for both groups but was only significant after LS/IMM because the overall decrease in glucagon was offset by the early postprandial increase after RYGB ([Fig. 1](#F1){ref-type="fig"}). After RYGB, adiponectin increased twofold and correlated with weight loss (*r* = 0.23; *P* = 0.003) but was unchanged after LS/IMM.

Insulin clearance increased 50% after LS/IMM and more than twofold after RYGB. There was greater improvement in early MCR (0--30 min) after RYGB ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}). The ISR increased in LS/IMM patients for all postprandial time points, even after adjusting for concurrent glucose ([Fig. 1](#F1){ref-type="fig"}). Although the ISR from 0 to 30 min was greater after RYGB than after LS/IMM, the rate was no longer different between the groups after adjusting for glucose ([Fig. 1](#F1){ref-type="fig"}). However, there was a precipitous decline in ISR from 60 to 120 min postprandially in RYGB patients that was not observed with LS/IMM ([Fig. 1](#F1){ref-type="fig"}).

There were greater changes in HOMA-IR and MI after RYGB ([Fig. 1](#F1){ref-type="fig"}). A higher MI correlated with a greater percentage weight loss for both LS/IMM and RYGB ([Fig. 1](#F1){ref-type="fig"}). The oDI increased threefold for LS/IMM and sixfold for RYGB and also correlated with the percentage of weight loss ([Fig. 1](#F1){ref-type="fig"}). BCGS increased significantly only for RYGB and was relatively unchanged in LS/IMM.

Gut Hormones {#s10}
------------

Values for GLP-1, GIP, and GLP-2 are presented in [Table 1](#T1){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}. The GLP-1 AUC increased after RYGB but not after LS/IMM. Despite an early postprandial increase in GIP levels, there was an overall significant decrease in the GIP AUC after RYGB. There was no change in GIP after LS/IMM. Peak GLP-1 or GIP levels were not associated with peak insulin or C-peptide levels (data not shown). The GLP-2 AUC decreased in LS/IMM patients but increased in RYGB patients.

![Fasting and postprandial changes in GLP-1 (*A*), GIP (*B*), and GLP-2 (*C*). Values are depicted in blue for LS/IMM and in red for RYGB. Open shapes and dashed lines denote baseline values, and closed shapes and solid lines reflect values at 1 year. Hatched bars denote baseline values, and solid bars denote values at 1 year. AUC is calculated from 0 to 120 min and is expressed ×10^3^. M0, month 0 (baseline); M12, month 12. \**P* \< 0.05 for within-group change. §*P* \< 0.05 for difference in change between groups.](db141870f2){#F2}

Correlation Analyses {#s11}
--------------------

Various factors were examined to determine predictors of HbA~1c~ at 12 months ([Table 2](#T2){ref-type="table"}). At 12 months, weight loss was significantly correlated with HbA~1c~ in both groups. Baseline HbA~1c~ was predictive of HbA~1c~ at 1 year in LS/IMM. Baseline 90-min C-peptide and greater early-phase (30 min) insulin secretion were associated with lower HbA~1c~ at 1 year in RYGB. A higher C-peptide index was correlated with lower HbA~1c~ for RYGB patients, and greater early postprandial insulin secretion at 1 year continued to correlate with lower HbA~1c~. The oDI was correlated with lower HbA~1c~ for both LS/IMM and RYGB. BCGS correlated with HbA~1c~ at 1 year for both groups; this association was independent of weight loss. BCGS did not correlate with weight loss, GLP-1 at 30 min, or total GLP-1 AUC (data not shown). Neither HOMA-IR nor MI were correlated with HbA~1c~ at 1 year for either group, but higher adiponectin levels at 1 year in RYGB patients correlated with lower HbA~1c~. After taking into account weight loss, adiponectin was no longer predictive of HbA~1c~ at 1 year in either group. Gut hormone levels before and after either intervention were not correlated with HbA~1c~.

###### 

Correlation between clinical and biochemical parameters and month 12 HbA~1c~

                           IMM      RYGB            
  ------------------------ -------- ------- ------- ----------
  Duration of T2DM         0.35     0.05    0.13    0.49
  BMI M0                   0.05     0.80    −0.15   0.42
  HbA~1c~ M0               0.43     0.01    0.08    0.68
  Insulin use M0           0.20     0.27    0.16    0.37
  C-peptide M0                                      
   Fasting                 −0.35    0.05    −0.31   0.09
   90-min                  −0.29    0.13    −0.50   0.007
  \% Weight loss           0.41     0.02    0.46    0.008
  C-peptide index                                   
   M0                      0.07     0.73    −0.35   0.07
   M12                     −0.42    0.02    −0.54   0.003
  HOMA-IR                                           
   M0                      −0.18    0.35    −0.13   0.47
   M12                     0.25     0.17    0.24    0.19
  MI                                                
   M0                      0.21     0.25    0.13    0.49
   M12                     −0.24    0.19    −0.10   0.58
  oDI                                               
   M0                      −0.005   0.98    −0.13   0.52
   M12                     −0.52    0.009   −0.69   \<0.0001
  BCGS                                              
   M0                      −0.01    0.96    −0.21   0.33
   M12                     −0.44    0.07    −0.69   0.0002
  ISR/glucose AUC~0--30~                            
   M0                      −0.28    0.18    −0.48   0.01
   M12                     −0.32    0.13    −0.71   \<0.0001
  GLP-1 AUC                                         
   M0                      −0.35    0.09    −0.09   0.67
   M12                     −0.08    0.65    0.06    0.76
  GLP-2 AUC                                         
   M0                      0.09     0.67    −0.07   0.73
   M12                     0.23     0.21    0.09    0.62
  GIP AUC                                           
   M0                      0.17     0.43    −0.05   0.80
   M12                     −0.01    0.94    0.19    0.29
  Glucagon AUC                                      
   M0                      0.02     0.93    −0.31   0.13
   M12                     0.05     0.77    0.08    0.69
  Adiponectin                                       
   M0                      0.01     0.95    0.002   0.99
   M12                     −0.17    0.34    −0.40   0.03

Clinical and biochemical parameters assessed with Spearman partial correlation, adjusting for age and sex.

AUC is calculated from 0 to 120 min, unless otherwise indicated.

M0, month 0; M12, month 12.

Discussion {#s12}
==========

We assessed pancreatic function and gut hormone changes after LS/IMM, alone or with RYGB, to determine factors associated with glycemic improvement after RYGB that may help identify patients most likely to derive the greatest glycemic benefit from surgery. As expected, fasting glucose and HbA~1c~ improved in both groups but more so after RYGB; unexpectedly, the glucose AUC decreased similarly in both groups. We found that when insulin and gut hormone responses are compared between treatment groups, it is important to consider altered dynamics after RYGB that are likely due to accelerated transit and absorption of nutrients ([@B12]--[@B14]). Therefore, the discussion below considers both fasting and postprandial changes.

The significant decline in total insulin response after RYGB disguises a greater early postprandial peak in insulin secretion. RYGB patients experienced a rapid insulin increase early after meal ingestion, followed by a precipitous decline, whereas insulin secretion increased in LS/IMM patients and remained elevated. The early postprandial increase in insulin secretion after RYGB was significantly associated with lower HbA~1c~. C-peptide and insulinogenic indices both increased and were correlated with lower HbA~1c~ after RYGB but remained unchanged after LS/IMM. Although higher insulin secretion may be the expected response to an early glycemic stimulus with altered nutrient transport, the correlation between early insulin secretion and improved HbA~1c~ suggests that RYGB improves intrinsic β-cell glucose sensitivity.

Greater early improvement in hepatic insulin sensitivity may be partly responsible for improved insulin clearance after RYGB, as noted by others ([@B15]); however, postprandial metabolic clearance was similar in both groups. Insulin sensitivity was several-fold greater after RYGB than after LS/IMM. The MI, used as a measure of peripheral insulin sensitivity ([@B10]), was associated with weight loss in both groups but did not correlate with HbA~1c~ after 1 year. β-Cell function (oDI) showed greater improvement after RYGB and was significantly associated with glycemia and weight loss at 1 year in both groups. BCGS, although unchanged after LS/IMM and markedly increased after RYGB at 1 year, correlated significantly with improved HbA~1c~ for both treatment groups, even after adjusting for weight loss. Taken together, the significant association of BCGS and oDI with improved HbA~1c~ after 1 year highlights the importance of β-cell function and sensitivity in determining glycemic control, regardless of weight loss.

Altered gut hormone secretion has been proposed as an important mechanism for improved glycemia after RYGB ([@B2]). Postprandial secretion of GLP-1 has been shown to substantially and durably increase after RYGB but not after laparoscopic adjustable gastric banding or diet-induced weight loss ([@B16],[@B17]). Our results corroborate earlier studies demonstrating an exaggerated increase in the GLP-1 AUC after RYGB without a significant change in LS/IMM. GLP-1 levels did not correlate with HbA~1c~ at 1 year, in contrast to other studies that have implicated GLP-1 as a predictor of remission ([@B18]). Some studies have implicated an exaggerated GLP-1 response as a mediator of improved β-cell function after RYGB ([@B14],[@B19]), but BCGS was not associated with GLP-1 in our study. Measurements of peripheral levels of GLP-1, however, may not reflect GLP-1 receptor action ([@B20]).

The insulin-to-glucagon molar ratio in RYGB patients decreased, which is consistent with relative hyperglucagonemia after RYGB, as proposed by Camastra et al. ([@B21]). Given that glucagon and GLP-1 are both derived from preproglucagon, it is possible that relative hyperglucagonemia is due to aberrant cleavage within the intestinal L cells after RYGB and/or lack of α-cell suppression ([@B22]). GLP-2, another product of preproglucagon that is cosecreted with GLP-1 in equimolar amounts, is similarly increased after RYGB. GLP-2 directly affects bowel mucosa by increasing the absorptive surface area, which may limit malabsorption and account for how well surgery is tolerated ([@B23]). GLP-2 has also been shown to stimulate glucagon secretion ([@B24]).

HbA~1c~ at 12 months correlated most strongly with weight loss for both intervention groups. BCGS and oDI also correlated with lower HbA~1c~ in both groups, and the association was independent of weight loss. Before surgery, a greater C-peptide index and greater 90-min postprandial C-peptide level were predictive of lower HbA~1c~ at 1 year, suggesting that residual β-cell function plays an important role in remission. After 1 year, these parameters and greater early insulin secretion continued to correlate with lower HbA~1c~ in RYGB patients. C-peptide and insulinogenic indices were essentially unchanged in LS/IMM patients, consistent with continued impaired insulin secretion. For LS/IMM patients, the only baseline predictor of lower HbA~1c~ at 1 year was HbA~1c~, showing that aside from weight loss, different mechanisms mediate improvement in glycemia in LS/IMM versus RYGB patients.

In summary, we have shown that improved β-cell function and BCGS contribute significantly to improved glycemia regardless of weight loss and intervention. Greater insulin secretory capacity is predictive of outcome after RYGB, which may be used to identify surgical candidates most likely to achieve the greatest glycemic benefit. Optimization of the surgical procedure to maximize weight loss in combination with targeted therapies that enhance β-cell function are likely to improve surgical outcomes.
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